Multidimensional biomarker predicts disease control
Cofactor Genomics,
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
The immunotherapy nivolumab has today been made available on the Cancer Drugs Fund (CDF) for patients with head and neck cancer…
The immunotherapy nivolumab will not be recommended for the treatment of patients with relapsed or metastatic head-and-cancer…
NICE drops recommended use of cancer drug nivolumabRelated items from OnMedicaNHS cancer patients still denied treatments…